首页> 外文期刊>Bioorganic and medicinal chemistry >Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity
【24h】

Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity

机译:新型HDAC8抑制性2,5-二取代-1,3,4-恶二唑类化合物的合成及抗癌活性

获取原文
获取原文并翻译 | 示例
           

摘要

Oxadiazole is a heterocyclic compound containing an oxygen atom and two nitrogen atoms in a five-membered ring. Of the four oxadiazoles known, 1,3,4-oxadiazole has become an important structural motif for the development of new drugs and the compounds containing 1,3,4-oxadiazole cores have a broad spectrum of biological activity. Herein, we describe the design, synthesis and biological evaluation of a series of novel 2,5-disubstituted 1,3,4-oxadiazoles (10a-10j) as class I histone deacetylase (HDAC) inhibitors. The compounds were designed and evaluated for HDAC8 selectivity using in silico docking software (Glide) and the top 10 compounds with high dock score and obeying Lipinski's rule were synthesized organically. Further the biological HDAC inhibitory and selectivity assays and anti-proliferative assays were carried out. In in silico and in vitro studies, all compounds (10a-10j) showed significant HDAC inhibition and exhibited HDAC8 selectivity. Among all tested compounds, 10b showed substantial HDAC8 inhibitory activity and better anticancer activity which is comparable to the positive control, a FDA approved drug, vorinostat (SAHA). Structural activity relation is discussed with various substitutions in the benzene ring connected on 1,3,4-oxadizole and glycine/alanine. The study warranted further investigations to develop HDAC8-selective inhibitory molecule as a drug for neoplastic diseases. Novel 1,3,4-oxadizole substituted with glycine/alanine showed HDAC8 inhibition. (C) 2016 Elsevier Ltd. All rights reserved.
机译:恶二唑是在五元环中含有氧原子和两个氮原子的杂环化合物。在已知的四种恶二唑中,1,3,4-恶二唑已成为开发新药的重要结构基序,并且包含1,3,4-恶二唑核心的化合物具有广泛的生物活性。在这里,我们描述了一系列新型2,5-二取代的1,3,4-恶二唑(10a-10j)作为I类组蛋白脱乙酰基酶(HDAC)抑制剂的设计,合成和生物学评估。使用计算机对接软件(Glide)设计和评估化合物的HDAC8选择性,并有机合成高对接得分最高且遵循Lipinski规则的前10种化合物。此外,进行了生物学HDAC抑制和选择性测定以及抗增殖测定。在计算机和体外研究中,所有化合物(10a-10j)均显示出显着的HDAC抑制作用并显示出HDAC8选择性。在所有测试的化合物中,10b表现出显着的HDAC8抑制活性和更好的抗癌活性,可与FDA批准的伏立诺他(SAHA)阳性对照相媲美。讨论了与1,3,4-恶二唑和甘氨酸/丙氨酸连接的苯环中各种取代基的结构活性关系。该研究值得进一步研究,以开发HDAC8选择性抑制分子作为治疗肿瘤疾病的药物。用甘氨酸/丙氨酸取代的新型1,3,4-恶二唑显示出HDAC8抑制作用。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号